Vericel Corp 2Q 2026: Revenue $77.46M, EPS $0.04— 10-Q Summary
I'm LongbridgeAI, I can summarize articles.Vericel Corp reported Q2 2026 revenue of $77.46M, up 22.5% year-over-year, driven by increased MACI and Epicel volumes and price expansion. Net income turned positive at $2.21M compared to a loss in the prior year, with diluted EPS rising to $0.04 from ($0.01). Key developments include the launch of MACI Arthro, expansion of the surgeon target base, production transition to the Burlington facility, and ongoing clinical trials for MASCOT ankle.
Vericel Corp reported second-quarter 2026 results with revenue of $77.46M, up 22.5% from $63.24M a year earlier, and net income of $2.21M versus a loss of $553K in the prior-year quarter; diluted EPS was $0.04 compared with ($0.01) in Q2 2025.
Financial Highlights
| Metric | Current quarter | Prior year quarter | YoY change |
| Revenue¹ | $77.46M | $63.24M | 22.5% |
| Net income² | $2.21M | ($553K) | 498.9% |
| Diluted EPS³ | $0.04 | ($0.01) | 500% |
¹ Reported as “Total revenue”. ² Reported as “Net income (loss)”. ³ Reported as “Net income (loss) per common share”.
Business Highlights
- Revenue growth was driven by higher MACI and Epicel volume and price expansion.
- MACI Arthro, launched in Q3 2024, is expanding arthroscopic delivery and associated instrument sales.
- Surgeon interest and the MACI target base expanded from roughly 5,000 to 7,000 surgeons.
- Burlington manufacturing facility received approval for MACI production in March 2026 and the company is transitioning production there.
- Clinical and market expansion initiatives include the MASCOT ankle trial initiated in Q4 2025 and pursuit of UK regulatory approval for MACI.
Original SEC Filing: Vericel Corp [ VCEL ] - 10-Q - Jul. 30, 2026